Real-world (Rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France and Germany

被引：0
|
作者：
Campone, M. [1 ]
Frenel, J-S. [1 ]
Kiver, V. I. I. [2 ,3 ,4 ]
Woeckel, A. [5 ]
Kerscher, A. G. [6 ]
Krebs, M. [6 ]
Leal, C. S. [7 ]
Saglimbene, V. M. [8 ]
Trankov, N. [9 ]
Sadetsky, N. [10 ]
Sjekloca, N. [11 ]
Libert, O. [12 ]
Kaushik, A. G. [13 ]
Bocquet, F. [14 ]
机构：
[1] ICO Inst Cancerol Ouest Rene Gauducheau, Dept Med Oncol, St Herblain, France
[2] Charite Univ Med Berlin, Breast Ctr, Dept Gynecol, Berlin, Germany
[3] Free Univ Berlin, Berlin, Germany
[4] Humboldt Univ, Berlin, Germany
[5] Univ Hosp Wurzburg, Dept Obstet & Gynecol, Wurzburg, Germany
[6] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany
[7] IQVIA, Epidemiol & Database Studies, Porto Salvo, Portugal
[8] IQVIA Italy, EMEA Real World Methods & Evidence Generat, Milan, Italy
[9] IQVIA, EMEA Real World Methods & Evidence Generat, Sofia, Bulgaria
[10] Gilead Sci Inc, RWE Oncol, Foster City, CA USA
[11] Gilead Sci Europe Ltd, Global Med Affairs, Stockley Pk, England
[12] Gilead Sci SAS, Med Affairs, Boulogne, France
[13] Gilead Sci Inc, Hlth Econ Outcomes Res, Foster City, CA USA
[14] Inst Cancerol Ouest, Data Factory & Analyt, St Herblain, France
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.322
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
374P
引用
收藏
页码：S375 / S376
页数：2
相关论文
共 50 条
  • [41] Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive (HR+)/HER2 receptor-negative (HER2-) metastatic breast cancer (MBC): A real life multicenter Italian study
    Palumbo, R.
    Torrisi, R.
    Quaquarini, E.
    Sottotetti, F.
    Gambaro, A.
    Collova, E.
    Ferzi, A.
    Fava, S.
    Agostinetto, E.
    Tagliaferri, B.
    Licata, L.
    Teragni, C.
    Bernardo, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [42] Palbociclib (PAL) in male patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Pt characteristics and treatment (Tx) patterns from the POLARIS study
    Blum, J. L.
    Dicristo, C.
    Gordon, D.
    Karuturi, M.
    Oubre, D.
    Jepsen, E.
    Cuevas, J.
    Lakhanpal, S.
    Zhang, Z.
    Drucker, M.
    Wang, Y.
    Tripathy, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S68 - S69
  • [43] Management of early-stage hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a real-word setting in Germany: A patient perspective
    Jackisch, C.
    Banys-Paluchowski, M.
    Korfel, A.
    Stoffregen, C.
    Otto, T.
    Brown, J.
    Sanderson, I.
    Rider, A.
    Lueftner, I.
    ANNALS OF ONCOLOGY, 2022, 33 : S156 - S157
  • [44] Trends in the choice of first line treatment for hormone - responsive (HR plus ), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): Results of a multicentric Italian observational study.
    D'Alonzo, Alessia
    Bighin, Claudia
    Puglisi, Fabio
    DeLaurentiis, Michelino
    Fontana, Andrea
    Pugliese, Palma
    Arpino, Grazia
    Poggio, Francesca
    Vaglica, Marina
    Dellepiane, Chiara
    Blondeaux, Eva
    Conte, Benedetta
    Cognetti, Francesco
    Garrone, Ornella
    Pastorino, Simona
    Ceppi, Marcello
    Del Mastro, Lucia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Trends in the choice of first line treatment for hormone - responsive (HR1), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study
    Alonzo, A. D'
    Bighin, C.
    Puglisi, F.
    Gerratana, L.
    De laurentis, M.
    Fontana, A.
    Pugliese, P.
    Ferzi, A.
    Montemurro, F.
    Arpino, G.
    Poggio, F.
    Vaglica, M.
    Dellepiane, C.
    Blondeaux, E.
    Benedetta, C.
    Cognetti, F.
    Garrone, O.
    Turletti, A.
    Pastorino, S.
    Del Mastro, L.
    ANNALS OF ONCOLOGY, 2017, 28 : 25 - 25
  • [46] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [47] The real-world Hellenic disease management patterns with everolimus (EVE) for women with hormone-receptor-positive (HR plus ), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (aBC): 'The MIRROR' study
    Zagouri, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S370 - S370
  • [48] Predictors of efficacy in patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2-ABC): Subgroup analyses of PALOMA-3
    Rugo, H.
    Cristofanilli, M.
    Loibl, S.
    Harbeck, N.
    Demichele, A.
    Iwata, H.
    Park, Y. H.
    Brufsky, A.
    Theall, K. Puyana
    Huang, X.
    McRoy, L.
    Bananis, E.
    Turner, N. C.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S7 - S8
  • [49] registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Tripathy, D.
    Kaufman, P.
    Brufsky, A.
    Mayer, M.
    Yood, M.
    Wang, L.
    Brammer, M.
    Yardley, D.
    Tan-Chiu, E.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] Disease features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients
    Wang, Jinhao
    Liu, Yaxin
    Shao, Bin
    Dong, Hang
    Zheng, Tiantian
    Du, Pan
    Jia, Shidong
    King, Bonnie
    Wang, Jing
    Liu, Xiaoran
    Li, Huiping
    CANCER RESEARCH, 2023, 83 (05)
12345